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This article complements a paper from Kahn and Zinman which reviews the importance of 
ADOPT to PPAR-γ agonists.  In that context this article does not seek to be a balanced view 
of the relative merits of sulfonylureas, metformin and thiazolidinediones. 
 
The ADOPT study was conceived in the hope that the seemingly inexorable decline in islet 
B-cell function described with metformin, sulfonylureas and insulin in the UK Prospective 
Diabetes Study (UKPDS) might be stopped or inhibited to a major degree by PPAR-γ 
agonists, in particular rosiglitazone (1,2).  It was already well recognized that the rapid early 
efficacy of sulfonylureas in lowering glucose was not retained to 12 months, and that 
metformin and thiazolidinediones had slow onset of action over months, so the design of the 
study necessarily had to enable decline of measures of blood glucose control to be assessed 
for a considerable period from 1 year onwards.  However the extent (degree and time) to 
which this early efficacy of the sulfonylureas in protecting against hyperglycaemia would 
persist was not accurately known.  The study also provided a good opportunity to compare 
durability of effect of the three classes of drug directly in the context some shorter-term 
studies published since (3). 
Metformin is currently well established as first line therapy in people with Type 2 diabetes, 
usually after lifestyle measures fail to achieve HbA1c levels of <6.5 %, although some 
consensus (as opposed to evidence-based) guidelines have suggested initiation immediately 
from diagnosis (4,5).  This review will not challenge those ideas, although the evidence is not 
as strong as sometimes assumed.  The exceptions to first line metformin use are where 
metformin is contraindicated, perhaps where someone is not overweight, and where 
presentation glucose levels are high and the rapid effect of a sulfonylurea is needed.  In 
situations where metformin is contraindicated, or as second line add-on therapy to metformin 
when target levels are no longer met, the alternative choice to a sulfonylurea would be a 
thiazolidinedione or possibly a gliptin (it is assumed insulin would not usually be the 
preference of a person with diabetes at this stage) (4,5).  ADOPT was not a combination 
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therapy study, but a host of studies in recent years, where glucose-lowering drugs were 
compared in monotherapy or in various combinations, suggest that outcomes are not 
different except for the exacerbation of hypoglycaemia.  Accordingly in this review it will be 
assumed that the findings of a monotherapy study (ADOPT) can be extended to the more 
usual role of sulfonylureas and thiazolidinediones in combination with metformin. 
A valid review of ADOPT and other longer term studies of oral glucose-lowering drugs 
(OGLDs) is hampered by three major issues.  Firstly, both the reader of the papers and the 
author of this review have only access to averaged data.  This can disguise the true nature of 
the changes occurring in individual people particularly were rescue therapies are introduced 
and/or data are censored at some point in deterioration of glucose control (Figure 1).  
Secondly very high drop out rates from studies as in ADOPT are of concern, particularly 
where the major outcome variable might cause dropout through dissatisfaction (as in studies 
of blood glucose control and body weight); no amount of data snooping can provide absolute 
reassurance of hidden biases.  Thirdly data on changes in of islet B-cell function may be 
problematic where an insulin secretagogue (including sulfonylureas) is being used, and with 
HOMA analysis once glucose control has deteriorated with time (6).   
 
Criteria of a successful glucose-lowering medication     
The primary purpose of ADOPT was not to answer the question as to whether any of the 
three medications was better overall than the others, but rather specifically to address the 
issue of durability of blood glucose control in the longer-term.  In their analysis, the authors 
have not for example addressed the question of which medication gave the best control over 
1, 2, 3 and 4 years.  Clinically however the issue of success at varying intervals is the critical 
one – health in chronic disease is not judged by health outcomes at any one time (and 
ultimately everyone is dead), but rather by quality of life over periods of years.  Furthermore 
the EDIC trial outcomes (in people with Type 1 diabetes) remind us that early and tight blood  
glucose control can effectively delay the point at which a cardiovascular event occurs (7); 
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that study and the epidemiological analysis of the UKPDS suggest that a useful period of 
good blood glucose control in preventing a cardiovascular event (an improvement in HbA1c of 
≥1.0 %) is as short as 2 years, and would be proportionately shorter for larger improvements 
(7,8).   
A balance to improved overall blood glucose control are issues which might worsen health, 
or worsen perceived well-being.  The familiar health issues which affect sulfonylureas and 
thiazolidinediones are putative worsening of cardiovascular outcomes (possible adverse 
cardiac effects on one hand, and exacerbation of cardiac failure from fluid retention on the 
other), and of hypoglycaemia with the sulfonylureas, together with the concerns arising from 
the DREAM study in regard of non-cardiac failure CV outcomes for rosiglitazone, and of 
osteoporotic effects (9,10).  In regard of well-being the issues which arise again include fluid 
retention (oedema) and hypoglycaemia, but in addition body weight gain.  The last may also 
have add-on health consequences outside the metabolic area through non-linear 
exacerbation of such conditions as knee osteoarthrosis and sleep apnoea, with significant 
impact on future quality of life.              
Assessment of the success of a medication can only be made in the context of its cost-
effectiveness.  Newer medications, such as thiazolidinediones, are only easily available to 
the well insured, those in some socialist medical systems which have approved them for 
reimbursement, and in some countries where patent laws are not applied.  Even where 
insurance or reimbursement are available, health care resources are not unlimited, and it 
behoves funders in the interest of the populations they serve to determine where a 
medication is properly positioned on the patient-care pathway.  That issue will therefore also 
be addressed in this article.   
In comparing glucose-lowering therapies the following questions can then be set:           
1. Over time courses of 1, 2, 3, and 4 years how do sulfonylureas match up to 
thiazolidinediones (and metformin) in terms of amelioration hyperglycaemia (avoidance 
of HbA1c >6.5 %)? 
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2. How significant are the direct side effects of the therapies, and in particular 
hypoglycaemia and fluid retention, both to other health risk and current quality of life? 
3. How does ADOPT impact on the concerns over cardiovascular safety of sulfonylureas 
(and thiazolidinediones)? 
4. Of what importance are issues of weight gain, and how does the large quantitative 
difference between sulfonylureas and thiazolidinediones make a difference to patient 
choice? 
5. What is the balance of cost impact and cost effectiveness issues? 
 
Judgement on the medications 
Glucose-lowering efficacy 
In ADOPT blood glucose control was considerably better with the sulfonylurea than with 
metformin or rosiglitazone over the first 2 months of therapy, although the effect is difficult to 
quantify accurately as the first published data point is at 2 months, and HbA1c is a lagging 
measure.  Nevertheless comparison of the FPG and HbA1c results would suggest that the 
effect of the sulfonylurea was nearly instantaneous, as the latter has already fallen markedly 
by 2 months, a fall 2-3 times greater than for the other medications (2). 
This change is echoed over the first year (Table 1).  Indeed the average blood glucose 
control was better with the sulfonylurea in the period 2-12 months, the intercept with the 
metformin line occurring at the end of 1 yr and only at 18 months with rosiglitazone (Figure 
2).  Notably, overall glucose control really only began to diverge between the three groups at 
3 years, and in years 2 and 3 differed little between the three treatments.  Accordingly 
average glucose control over the first 3 years was almost exactly the same for the three 
therapies (Table 1), with a possible slight advantage to the sulfonylureas. 
None of the three therapies proved satisfactory as monotherapy in the majority of people, as 
judged by the mean HbA1c and a criterion of <6.5 %.  However the data suggest that these 
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agents lower HbA1c by around 0.5 % from the kind of baseline levels reported in the ADOPT 
study, a result almost exactly consistent with 18-month data from data with these groups of 
medications in the RECORD study (11).  As an approximation it is then possible, with 
reservations, to use the ADOPT paper's data on time to failure at an HbA1c of 7.0 % for 
glibenclamide alone as if it was used in combination with metformin with a failure criterion of 
≥6.5%.  This shows that on average the sulfonylurea would be successful in the ADOPT 
population to 2.75 years, a useful duration of effect clinically.  Using the ADOPT authors 
secondary criterion of success in maintaining fasting plasma glucose to <7.8 mmol/l (140 
mg/dl) as monotherapy, glibenclamide was successful at 4 years in 67 % of patients, a useful 
result, and far in excess of the success rates for medications in many areas of medicine. 
Therapy side effects 
The main side effects to be considered are hypoglycaemia for sulfonylureas, fluid retention 
and cardiac failure (CHF) for the thiazolidinedione, and other cardiovascular safety for both.  
This review is not concerned with the thiazolidinedione, but since the drugs do compete for a 
role in second line therapy (and increasingly also with the gliptins), it should be noted that the 
issues of fluid retention, use of loop diuretics (which carry morbidity) and bone changes with 
that class of drugs are confirmed by ADOPT as real, while the sceptre of an adverse non-
CHF cardiovascular profile raised in the DREAM study has been ameliorated (9).                  
Even after subtraction of CHF events, numerically there were less CVD events in ADOPT in 
the glibenclamide group than in the metformin and rosiglitazone groups, namely 32, 40, and 
39 patients affected respectively.  Figures for myocardial infarction are 18, 27 and 23 
patients respectively, with 3, 2, and 2 fatalities; data on stroke and peripheral arterial disease 
were unremarkable.  It should be noted that these data should be interpreted as safety data 
and not subject to forms of statistical analysis, which would be unsafe given the low 
statistical power for in outcomes which were not part of the study design.  Nevertheless the 
data does strongly suggest that long-held theoretical concerns about adverse effects of 
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sulfonylureas, and in particular glibenclamide, on prevention of ischaemic preconditioning in 
cardiac muscle are unwarranted (12).   
The issue of hypoglycaemia with sulfonylureas is an important one, and in some people can 
have significant impact on quality of life through employment, recreation, or even falls and 
coma particularly in the infirm elderly (13).  In the general diabetes population treated with 
these medications it is not such an issue, as evidenced for example by the UKPDS (1).  
Unfortunately the hypoglycaemia data available from the ADOPT study is very poor quality, 
and small in quantity.  Thus hypoglycaemia was not confirmed by a plasma glucose 
measurement as is usual in insulin studies, so that a prevalence rate (patients affected) of 
around 10-12 % was recorded even for people on rosiglitazone or metformin monotherapy.  
Subtraction of this figure suggests that perhaps 28 % of people on glibenclamide might have 
had hypoglycaemic symptoms, and just 0.6 % an investigator-defined serious event, at some 
time during the 5 years of the study. It is not possible from the data given to calculate the 
event rate (episodes per year), or the number of people with a recurrent problem.   
Glibenclamide is easily the most notorious member of its class as far as hypoglycaemia is 
concerned, not just in clinical practice but also in terms of national serious adverse event 
reporting, particularly in association with renal disease (12,14).  Indeed this is one reason it is 
often chosen as a comparator in oral therapy drug trials, the other being its continued 
widespread usage globally.   Data on the extent of this problem is difficult to come by, but the 
incidence of events is probably 2-10 times higher than with other sulphonylureas (12). In the 
2-year pioglitazone-gliclazide study gliclazide seems to have been associated with 10-13 % 
of patients having an event in 2 years (n=952 exposed), with no mention of events giving rise 
to serious health problems (3).  The UKPDS used only the two drugs with the worst 
reputation in this field (glibenclamide and chlorpropamide) finding a serious hypoglycaemia 
rate of around 0.5 % of patients per year (1).  The impression then is that ADOPT does not 
worsen our impression that hypoglycaemia is a problem in only in a minority of people using 
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sulfonylureas, and that careful choice of agent and self-monitoring are important in avoiding 
the issue in routine clinical practice. 
Weight gain 
The body weight trajectory in participants randomized to glibenclamide in ADOPT is 
reassuring (unlike that for the thiazolidinedione) and cannot really be called a side effect.  
Again it must be noted that stimulation of appetite is a particular problem with glibenclamide 
compared to other sulfonylureas, due to its hypoglycaemic tendency around lunch-time in 
people in good blood glucose control.  Initial weight gain appears (graphically) to be 2.5 kg in 
around 1 year, not inconsistent with the average improvement of 0.8 % in HbA1c, and entirely 
consistent with amelioration of urinary glycosuria and a >10 % reduction in blood glucose 
concentration driven glucose metabolism (15).  Thereafter body weight fell slowly over the 
rest of the study, consistent with the slow deterioration of blood glucose control and secular 
trends of weight with age in the general population.  This was true despite stimulation of 
endogenous insulin secretion, which by HOMA analysis was nearly normalized by 
glibenclamide at 6 months (this assumes equivalence between the ADOPT and Oxford 
insulin assays) and remained above baseline and numerically higher than for the other 
medications out to 4 years.      
This weight change would not then be expected to have any adverse metabolic effect.  Little 
confirmatory information is available from the study itself, though overall insulin sensitivity 
seems to have improved with glibenclamide during the study.  Data on lipids are not 
available through the study, but at 4 years serum LDL cholesterol concentration was not 
different from metformin, though HDL cholesterol marginally (3 %) lower.     
In cosmetic terms a weight gain of 2.5 kg in one year is a minor but significant problem, but 
stabilization of body weight over a period of 4 years subsequently is likely to be welcomed by 
many people with diabetes.   
Costs and cost-effectiveness 
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Costs of diabetes care are coming into ever sharper focus at present driven by three issues.  
The first of these is the welcome acknowledgement of the reality that the real costs of 
diabetes come from failures of preventative medicine, that is when the complications 
develop.  The second is the expanding prevalence of diabetes, driven by overeating and 
underactivity, together with increase life expectancy through better application of those 
preventative measures and the longer survival of people developing diabetes at a younger 
age (16).  But the third issue is the increased costs of new technologies, notably medications 
and methods of giving them.  To put this in perspective, in the uncomplicated patient, items 
such as insulin pumps, inhaled insulin, new oral agents, new anti-platelet drugs, and new 
lipid lowering drugs can easily double or triple the total costs (not just the drug costs) of 
diabetes care.             
ADOPT is positive for sulfonylureas because the sister drugs of glibenclamide such as 
gliclazide and glipizide are widely available at generic prices, while having a better safety 
profile in regard of hypoglycaemia (12).  Put another way, over 3 years the glucose-lowering 
effect may be identical to a thiazolidinedione, but the cost:glucose-lowering ratio is some six 
times or so better for the sulfonylurea.  At present the comparative side effect profiles would 
not suggest that any added costs of therapy were higher for the sulfonylurea, and perhaps 
the reverse.  The only thing that could change this analysis would be demonstration of a 
fundamental improvement in preservation of islet B-cells that could reduce the need for 
further (expensive) therapies later in the course of the disease, but meanwhile the argument 
is more around the order of use of the therapies second or third line.   
 
Conclusions 
ADOPT is good news for sulfonylureas.  In the guise of glibenclamide they are found to be 
safe, very effective initially, and equally effective over 3 years to the competitor medications.  
Weight gain is moderate and physiological, and insulin sensitivity and islet B-cell function are 
not adversely affected.  They remain inexpensive and highly cost-effective (17,18).  But 
 10 
combination therapy with metformin will be needed for most people within the first year of 
from diagnosis, if glucose-control targets are to be met.   
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Table 1.  Blood glucose control with glibenclamide (glyburide) compared to metformin and 
rosiglitazone in the ADOPT study (1) 
   glibenclamide metformin  rosiglitazone 
HbA1ca 
  mean in year 1 (%)b 6.5 6.7 6.8 
  mean in year 2
 
(%) 6.8 6.7 6.8 
  mean in year 3
 
(%) 7.0 6.9 6.8 
  3-yr meanb 6.7 6.8 6.8 
HbA1c <7.0 %  
  at 4 yr (% patients) 26 36 40 
  time to ≥7.0 % (yr) 2.75 3.75 5.00 
FPG <10.0 mmol/l (180 mg/dl)   
    at 3 yr (% patients) 84 92 93 
   at 4 yr (% patients) 78 88 90 
FPG <7.8 mmol/l (140 mg/dl)  
  at 4 yr (% patients) 67 76 85 
a
, this data is read from graphs, and is thus subject to small errors 
b
, excludes the baseline measurement, and thus glucose control over 0-2 months when it is 
considerably better with the sulfonylurea  
Baseline HbA1c was 7.4 % in all groups, and FPG 8.4 mmol/l (151-152 mg/dl) 
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Figure 1.  Diagram to show how very non-linear deterioration in 
individual blood glucose control with censoring on starting insulin (solid 
lines, five patients) can produce an apparently linear average decline 
(dashed line).  Many other non-linear examples can produce linear 
averages.  
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Figure 2.  Time course of HbA1c in the ADOPT study redrawn to show average blood glucose 
control over the first 3 years (1).  Data from 4 years onward is omitted as invalid (only 55-
20 % of randomized participants continuing).  ∆, glibenclamide, ○, metformin,  □, 
rosiglitazone 
 
 
 
 
 
